DK1940465T3 - Ny anvendelse af anti-IL-1beta-antistoffer - Google Patents

Ny anvendelse af anti-IL-1beta-antistoffer

Info

Publication number: DK1940465T3
Authority: DK; Denmark
Prior art keywords: new use; 1beta antibodies; 1beta; antibodies; new
Prior art date: 2005-10-26

Application number

DK06826560.2T

Other languages

English (en)

Inventor

Phil Lowe

Thomas Jung

Hermann Gram

Timothy Wright

Trevor Mundel

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2006-10-24

Publication date

2012-10-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1940465(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-10-24 Application filed by Novartis Ag filed Critical Novartis Ag

2012-10-22 Application granted granted Critical

2012-10-22 Publication of DK1940465T3 publication Critical patent/DK1940465T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Zoology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)

DK06826560.2T 2005-10-26 2006-10-24 Ny anvendelse af anti-IL-1beta-antistoffer DK1940465T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73043505P	2005-10-26	2005-10-26
US74212505P	2005-12-02	2005-12-02
PCT/US2006/041479 WO2007050607A2 (en)	2005-10-26	2006-10-24	Novel use of il-1beta compounds

Publications (1)

Publication Number	Publication Date
DK1940465T3 true DK1940465T3 (da)	2012-10-22

Family

ID=37806690

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK14191582.7T DK2848258T3 (da)	2005-10-26	2006-10-24	Behandling af familiær middelhavsfeber med anti-IL-1beta-antistoffer
DK06826560.2T DK1940465T3 (da)	2005-10-26	2006-10-24	Ny anvendelse af anti-IL-1beta-antistoffer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK14191582.7T DK2848258T3 (da)	2005-10-26	2006-10-24	Behandling af familiær middelhavsfeber med anti-IL-1beta-antistoffer

Country Status (29)

Country	Link
US (8)	US8105587B2 (da)
EP (5)	EP2332577A1 (da)
JP (4)	JP2009513645A (da)
KR (3)	KR20170038131A (da)
CN (2)	CN102861332A (da)
AU (1)	AU2006306280B2 (da)
BR (1)	BRPI0617830B8 (da)
CA (3)	CA2898369C (da)
CY (4)	CY1113378T1 (da)
DK (2)	DK2848258T3 (da)
ES (3)	ES2662420T3 (da)
HK (3)	HK1121041A1 (da)
HU (2)	HUE036973T2 (da)
IL (4)	IL190545A (da)
JO (2)	JO2826B1 (da)
LT (3)	LT2848258T (da)
LU (2)	LU92326I2 (da)
MA (1)	MA29919B1 (da)
NO (2)	NO345888B1 (da)
NZ (1)	NZ567222A (da)
PH (2)	PH12013501287A1 (da)
PL (2)	PL2848258T3 (da)
PT (2)	PT2848258T (da)
RU (2)	RU2468817C2 (da)
SI (2)	SI1940465T1 (da)
TN (1)	TNSN08189A1 (da)
TR (1)	TR201802449T4 (da)
TW (3)	TWI626056B (da)
WO (1)	WO2007050607A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2848258T3 (pl)	2005-10-26	2018-06-29	Novartis Ag	Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
AU2012203932B2 (en) *	2007-05-29	2014-04-24	Novartis Ag	New indications for anti-IL-I-beta therapy
RU2009148597A (ru)	2007-05-29	2011-07-10	Новартис АГ (CH)	Новые показания к применению при лечении антителами против il-1-бета
ES2398693T3 (es) *	2008-06-06	2013-03-21	Xoma Technology Ltd.	Métodos para el tratamiento de la artritis reumatoide
EP2196476A1 (en)	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
JP5913103B2 (ja)	2009-09-14	2016-04-27	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイトＴＨＥＲＥＧＥＮＴＳＯＦＴＨＥＵＮＩＶＥＲＳＩＴＹＯＦＣＯＬＯＲＡＤＯ，ａｂｏｄｙｃｏｒｐｏｒａｔｅ	酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
MX2012004412A (es) *	2009-10-15	2012-05-08	Abbott Lab	Proteinas de union a il-1.
LT2571532T (lt) *	2010-05-14	2017-08-10	Abbvie Inc.	Il-1 surišantys baltymai
AU2011361720B2 (en) *	2010-12-21	2017-04-27	Abbvie Inc.	IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
AU2012253422B2 (en)	2011-05-10	2015-08-13	Société des Produits Nestlé S.A.	Methods of disease activity profiling for personalized therapy management
WO2017153936A1 (en)	2016-03-10	2017-09-14	Novartis Ag	Chemically modified messenger rna's
CA3135012A1 (en)	2017-05-31	2018-12-06	Anjali Jain	Methods for assessing mucosal healing in crohn's disease patients
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en)	2017-06-22	2018-12-27	Novartis Ag	IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
US20210371511A1 (en)	2018-05-09	2021-12-02	Novartis Ag	Use of canakinumab
WO2020128637A1 (en)	2018-12-21	2020-06-25	Novartis Ag	Use of il-1 binding antibodies in the treatment of a msi-h cancer
US20220025036A1 (en)	2018-12-21	2022-01-27	Novartis Ag	Use of il-1beta binding antibodies
US20220056123A1 (en)	2018-12-21	2022-02-24	Novartis Ag	Use of il-1beta binding antibodies
EP3898675A1 (en) *	2018-12-21	2021-10-27	Novartis AG	Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
TWI793503B (zh) *	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
KR20230109107A (ko) *	2022-01-10	2023-07-19	(주)지아이이노베이션	글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5350683A (en) *	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
ATE300615T1 (de)	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1995001997A1 (en) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JPH08508415A (ja)	1993-12-14	1996-09-10	ユニバーシティーオブピッツバーグオブザコモンウェルスシステムオブハイヤーエデュケーション	結合組織疾患の全身的遺伝子治療
AU735648B2 (en)	1996-07-12	2001-07-12	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) *	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
JP2003500005A (ja)	1999-02-10	2003-01-07	インターリューキンジェネティックスインコーポレイテッド	ＩＬ−１β遺伝子の突然変異に基づく治療および診断
US6566554B1 (en) *	1999-07-16	2003-05-20	Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab)	Aminobenzophenones as inhibitors of IL-1β and TNF-α
CA2383451A1 (en)	1999-08-24	2001-03-01	Ariad Gene Therapeutics, Inc.	28-epirapalogs
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
WO2001087328A2 (en) *	2000-05-12	2001-11-22	Immunex Corporation	Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
EP2070921A1 (en)	2000-11-07	2009-06-17	Novartis Ag	Indolylmaleimide derivatives as protein kinase c inhibitors
AU2002355249A1 (en) *	2001-07-26	2003-02-17	Eli Lilly And Company	Interleukin-1 beta antibodies
WO2003014309A2 (en) *	2001-08-07	2003-02-20	Immunex Corporation	Interleukin-1 receptors in the treatment of diseases
ATE556482T1 (de)	2001-12-01	2012-05-15	Iskra Wind Turbines Ltd	Synchron-wechselstromgenerator mit einem bremsmechanismus
KR200268109Y1 (ko)	2001-12-06	2002-03-15	김정훈	편평형 무정류자 진동모터
ES2485841T3 (es)	2002-02-01	2014-08-14	Ariad Pharmaceuticals, Inc	Compuestos que contienen fósforo y usos de los mismos
MXPA04007124A (es)	2002-02-01	2004-10-29	Omeros Corp	Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
MXPA04007694A (es) *	2002-02-11	2004-11-10	Arkion Life Sciences Llc	Factor inhibidor de citosina purificada.
TWI324064B (en)	2002-04-03	2010-05-01	Novartis Ag	Indolylmaleimide derivatives
EP1578411A4 (en)	2002-12-09	2007-05-02	Univ Texas	PROCESS FOR SELECTIVE INHIBITION OF JANUS TYROSINE KINASE 3 (JAK3)
MXPA05007853A (es)	2003-01-24	2006-02-10	Applied Molecular Evolution	Antagonistas de il-1 beta humana.
GB0303337D0 (en) *	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
AU2005249503B2 (en) *	2003-11-10	2011-08-25	Vertex Pharmaceuticals Incorporated	ICE inhibitors for the treatment of autoinflammatory diseases
WO2005047906A1 (en)	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
ZA200602666B (en)	2004-01-12	2007-09-26	Cytopia Res Pty Ltd	Selective kinase inhibitors
DK1720893T3 (da) *	2004-02-26	2014-11-24	Baylor Res Inst	Sammensætninger og fremgangsmåder for den systemiske behandling af artritis
MXPA06014126A (es) *	2004-06-04	2007-07-18	Regeneron Pharma	Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
JP2009501128A (ja)	2005-01-20	2009-01-15	ユニバーシティーオブロチェスター	炎症疾患および炎症障害の研究および処置のための組成物および方法
WO2006102342A2 (en)	2005-03-18	2006-09-28	Microbia, Inc.	Production of carotenoids in oleaginous yeast and fungi
KR101502920B1 (ko)	2005-06-21	2015-03-17	조마 (유에스) 엘엘씨	ＩＬ-１β 결합성 항체 및 그의 단편
PL2848258T3 (pl) *	2005-10-26	2018-06-29	Novartis Ag	Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta

2006
- 2006-10-24 PL PL14191582T patent/PL2848258T3/pl unknown
- 2006-10-24 HU HUE14191582A patent/HUE036973T2/hu unknown
- 2006-10-24 SI SI200631412T patent/SI1940465T1/sl unknown
- 2006-10-24 EP EP10181100A patent/EP2332577A1/en not_active Withdrawn
- 2006-10-24 DK DK14191582.7T patent/DK2848258T3/da active
- 2006-10-24 RU RU2008120625/15A patent/RU2468817C2/ru active
- 2006-10-24 BR BRPI0617830A patent/BRPI0617830B8/pt active IP Right Grant
- 2006-10-24 LT LTEP14191582.7T patent/LT2848258T/lt unknown
- 2006-10-24 CN CN2012102904088A patent/CN102861332A/zh active Pending
- 2006-10-24 WO PCT/US2006/041479 patent/WO2007050607A2/en active Application Filing
- 2006-10-24 EP EP14191582.7A patent/EP2848258B1/en active Active
- 2006-10-24 SI SI200632245T patent/SI2848258T1/en unknown
- 2006-10-24 CN CN200680039395XA patent/CN101291693B/zh active Active
- 2006-10-24 PT PT141915827T patent/PT2848258T/pt unknown
- 2006-10-24 TR TR2018/02449T patent/TR201802449T4/tr unknown
- 2006-10-24 KR KR1020177008682A patent/KR20170038131A/ko not_active Application Discontinuation
- 2006-10-24 CA CA2898369A patent/CA2898369C/en active Active
- 2006-10-24 CA CA2626214A patent/CA2626214C/en active Active
- 2006-10-24 PT PT06826560T patent/PT1940465E/pt unknown
- 2006-10-24 ES ES14191582.7T patent/ES2662420T3/es active Active
- 2006-10-24 EP EP17199544.2A patent/EP3332807B1/en active Active
- 2006-10-24 ES ES17199544T patent/ES2944067T3/es active Active
- 2006-10-24 US US12/090,490 patent/US8105587B2/en active Active
- 2006-10-24 NO NO20200810A patent/NO345888B1/no unknown
- 2006-10-24 DK DK06826560.2T patent/DK1940465T3/da active
- 2006-10-24 AU AU2006306280A patent/AU2006306280B2/en active Active
- 2006-10-24 EP EP06826560A patent/EP1940465B1/en active Active
- 2006-10-24 JP JP2008537878A patent/JP2009513645A/ja not_active Withdrawn
- 2006-10-24 PL PL06826560T patent/PL1940465T3/pl unknown
- 2006-10-24 KR KR1020147035512A patent/KR101749388B1/ko active IP Right Grant
- 2006-10-24 NZ NZ567222A patent/NZ567222A/en not_active IP Right Cessation
- 2006-10-24 EP EP23155348.8A patent/EP4218815A3/en active Pending
- 2006-10-24 ES ES06826560T patent/ES2389110T3/es active Active
- 2006-10-24 CA CA2963828A patent/CA2963828A1/en not_active Abandoned
- 2006-10-24 KR KR1020087009981A patent/KR101518064B1/ko active IP Right Grant
- 2006-10-25 TW TW105103583A patent/TWI626056B/zh active
- 2006-10-25 TW TW101132057A patent/TWI537003B/zh active
- 2006-10-25 TW TW095139438A patent/TWI388335B/zh active
- 2006-10-29 JO JO2006387A patent/JO2826B1/en active
2008
- 2008-03-31 IL IL190545A patent/IL190545A/en active IP Right Grant
- 2008-04-23 MA MA30863A patent/MA29919B1/fr unknown
- 2008-04-25 TN TNP2008000189A patent/TNSN08189A1/en unknown
- 2008-05-23 NO NO20082344A patent/NO345140B1/no unknown
2009
- 2009-01-07 HK HK09100171.2A patent/HK1121041A1/xx unknown
2011
- 2011-10-27 US US13/283,165 patent/US8409576B2/en active Active
2012
- 2012-08-06 RU RU2012133522/15A patent/RU2571563C2/ru active
- 2012-09-24 CY CY20121100867T patent/CY1113378T1/el unknown
2013
- 2013-02-26 US US13/777,609 patent/US20130171167A1/en not_active Abandoned
- 2013-03-27 JP JP2013066205A patent/JP6061747B2/ja active Active
- 2013-06-18 PH PH12013501287A patent/PH12013501287A1/en unknown
- 2013-12-05 LU LU92326C patent/LU92326I2/fr unknown
- 2013-12-06 LT LTPA2013026C patent/LTC1940465I2/lt unknown
- 2013-12-13 CY CY2013046C patent/CY2013046I2/el unknown
2014
- 2014-03-16 JO JOP/2014/0120A patent/JOP20140120B1/ar active
2015
- 2015-06-03 HK HK15105300.7A patent/HK1204767A1/xx unknown
- 2015-07-28 US US14/810,556 patent/US9649377B2/en active Active
- 2015-10-02 JP JP2015196708A patent/JP6286403B2/ja active Active
2016
- 2016-05-02 IL IL245387A patent/IL245387B/en active IP Right Grant
2017
- 2017-04-11 US US15/484,459 patent/US20170218063A1/en not_active Abandoned
- 2017-08-04 JP JP2017151327A patent/JP2017206552A/ja active Pending
2018
- 2018-03-12 US US15/918,136 patent/US20180201674A1/en not_active Abandoned
- 2018-03-12 CY CY20181100301T patent/CY1120018T1/el unknown
- 2018-04-26 IL IL258983A patent/IL258983B/en active IP Right Grant
- 2018-06-11 HU HUS1800025C patent/HUS1800025I1/hu unknown
- 2018-06-11 LU LU00078C patent/LUC00078I2/fr unknown
- 2018-06-12 LT LTPA2018506C patent/LTC2848258I2/lt unknown
- 2018-06-12 CY CY2018018C patent/CY2018018I1/el unknown
- 2018-09-10 HK HK18111596A patent/HK1252316A1/zh unknown
2020
- 2020-06-19 US US16/906,118 patent/US20210147533A1/en not_active Abandoned
- 2020-06-23 PH PH12020500559A patent/PH12020500559A1/en unknown
- 2020-09-16 IL IL277406A patent/IL277406A/en unknown
2023
- 2023-02-28 US US18/175,849 patent/US20240083997A1/en active Pending

Also Published As

Publication number	Publication date
TW200803898A (en)	2008-01-16
US20080286266A1 (en)	2008-11-20
LT2848258T (lt)	2018-02-26
EP1940465B1 (en)	2012-08-01
PT1940465E (pt)	2012-10-03
LTC2848258I2 (lt)	2019-08-12
IL258983A (en)	2018-06-28
WO2007050607A3 (en)	2007-06-28
HK1252316A1 (zh)	2019-05-24
JO2826B1 (en)	2014-09-15
TWI388335B (zh)	2013-03-11
IL258983B (en)	2020-10-29
EP3332807A3 (en)	2018-06-20
NZ567222A (en)	2011-07-29
RU2571563C2 (ru)	2015-12-20
CY2013046I1 (el)	2015-11-04
IL277406A (en)	2020-11-30
EP2332577A1 (en)	2011-06-15
HUE036973T2 (hu)	2018-08-28
JP2013166757A (ja)	2013-08-29
AU2006306280A1 (en)	2007-05-03
US20210147533A1 (en)	2021-05-20
BRPI0617830B8 (pt)	2021-05-25
CY2013046I2 (el)	2015-11-04
LUC00078I2 (fr)	2018-08-14
TWI626056B (zh)	2018-06-11
HK1121041A1 (en)	2009-04-17
MA29919B1 (fr)	2008-11-03
CN102861332A (zh)	2013-01-09
CN101291693B (zh)	2012-10-03
PL2848258T3 (pl)	2018-06-29
CA2626214C (en)	2016-06-21
JP6061747B2 (ja)	2017-01-18
TW201302220A (zh)	2013-01-16
US20150322148A1 (en)	2015-11-12
EP4218815A3 (en)	2024-03-27
US20120039910A1 (en)	2012-02-16
TW201617097A (zh)	2016-05-16
ES2662420T3 (es)	2018-04-06
BRPI0617830A2 (pt)	2011-08-09
CY2018018I2 (el)	2018-12-12
RU2012133522A (ru)	2014-02-20
LU92326I2 (fr)	2014-02-05
PH12013501287B1 (en)	2016-02-01
CY1113378T1 (el)	2015-11-04
CN101291693A (zh)	2008-10-22
LTC1940465I2 (lt)	2017-12-11
KR101749388B1 (ko)	2017-06-20
IL245387B (en)	2019-09-26
KR20150013834A (ko)	2015-02-05
NO345140B1 (no)	2020-10-12
US9649377B2 (en)	2017-05-16
NO345888B1 (no)	2021-09-27
TR201802449T4 (tr)	2018-03-21
CA2626214A1 (en)	2007-05-03
SI1940465T1 (sl)	2012-10-30
US20180201674A1 (en)	2018-07-19
LU92326I9 (da)	2019-01-16
IL245387A0 (en)	2016-06-30
EP2848258B1 (en)	2017-12-13
HK1204767A1 (en)	2015-12-04
CA2898369C (en)	2017-06-20
US8105587B2 (en)	2012-01-31
CY1120018T1 (el)	2018-12-12
NO20200810A1 (no)	2008-07-22
HUS1800025I1 (hu)	2018-07-30
WO2007050607A2 (en)	2007-05-03
CY2018018I1 (el)	2018-12-12
JOP20140120B1 (ar)	2021-08-17
US8409576B2 (en)	2013-04-02
PT2848258T (pt)	2018-03-20
CA2963828A1 (en)	2007-05-03
ES2389110T3 (es)	2012-10-23
JP2009513645A (ja)	2009-04-02
DK2848258T3 (da)	2018-03-19
IL190545A0 (en)	2008-11-03
TWI537003B (zh)	2016-06-11
LTPA2018506I1 (lt)	2018-06-25
JP2016020377A (ja)	2016-02-04
EP3332807B1 (en)	2023-02-22
AU2006306280B2 (en)	2010-06-17
ES2944067T3 (es)	2023-06-19
KR101518064B1 (ko)	2015-05-06
IL190545A (en)	2016-09-29
SI2848258T1 (en)	2018-03-30
PH12013501287A1 (en)	2016-02-01
EP4218815A2 (en)	2023-08-02
EP3332807A2 (en)	2018-06-13
PL1940465T3 (pl)	2013-01-31
RU2468817C2 (ru)	2012-12-10
JP2017206552A (ja)	2017-11-24
US20130171167A1 (en)	2013-07-04
US20170218063A1 (en)	2017-08-03
EP1940465A2 (en)	2008-07-09
CA2898369A1 (en)	2007-05-03
NO20082344L (no)	2008-07-22
RU2008120625A (ru)	2010-01-20
KR20080059598A (ko)	2008-06-30
PH12020500559A1 (en)	2021-06-14
EP2848258A1 (en)	2015-03-18
BRPI0617830B1 (pt)	2020-10-20
JP6286403B2 (ja)	2018-02-28
KR20170038131A (ko)	2017-04-05
US20240083997A1 (en)	2024-03-14
TNSN08189A1 (en)	2009-10-30

Publication	Publication Date	Title
DK1940465T3 (da)	2012-10-22	Ny anvendelse af anti-IL-1beta-antistoffer
NO20190202A1 (no)	2008-05-19	Anvendelse av anti-CGRP antagonist antistoff
DK1802579T3 (da)	2014-01-20	Derivater af 3-arylaminopyridin
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
DK1730476T3 (da)	2021-06-21	Simplificeret måling af fluidegenskaber
DK1778618T3 (da)	2014-03-10	Syntese af triethylentetraminer
DK1720866T3 (da)	2011-11-21	Fremgangsmåde
DK1587542T3 (da)	2012-07-30	Anvendelse af anti-CD100-antistoffer
DK1964852T3 (da)	2013-07-08	Anti-ilt7-antistof
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff
DE602005027428D1 (de)	2011-05-26	Toner
DK1981859T3 (da)	2013-01-21	Fremstilling af delmopinol
DE602004019389D1 (de)	2009-03-26	Toner
DE602006003681D1 (de)	2009-01-02	Toner
DK1737891T3 (da)	2013-03-25	Anti-p-selectin-antistoffer
ATE501174T1 (de)	2011-03-15	Antikörper gegen madcam
DE602006020221D1 (de)	2011-04-07	Toner
ATE483732T1 (de)	2010-10-15	Madcam-antikörper
DK1917227T3 (da)	2013-05-27	Krystalformer af astaxanthin
NO20043305D0 (no)	2004-08-09	Preparation of lodixanol
DK2228656T3 (da)	2014-02-03	Kvantificering af allergener
NO20055643D0 (no)	2005-11-29	Preparation of lodixanol
DK1763520T3 (da)	2009-02-09	Anvendelse af trisubstituerede benzopyranoner
DE602005019013D1 (de)	2010-03-11	Tonerzusammensetzung
DK2301576T3 (da)	2012-12-10	Terapeutisk anvendelse af anti-CS1-antistoffer